Zacks Investment Research cut shares of MediWound Ltd. (NASDAQ:MDWD) from a hold rating to a sell rating in a research report released on Tuesday.
According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “
Several other brokerages have also commented on MDWD. SunTrust Banks, Inc. reaffirmed a buy rating on shares of MediWound in a report on Monday, June 26th. Aegis reaffirmed a buy rating and issued a $11.00 price objective on shares of MediWound in a report on Thursday, May 25th. Finally, Oppenheimer Holdings, Inc. set a $10.00 price objective on MediWound and gave the stock a buy rating in a report on Monday, May 8th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. MediWound presently has a consensus rating of Buy and a consensus price target of $10.19.
Shares of MediWound (NASDAQ MDWD) traded up 6.45% during mid-day trading on Tuesday, reaching $6.60. The company had a trading volume of 37,223 shares. The firm has a 50 day moving average of $6.90 and a 200-day moving average of $6.45. The stock’s market capitalization is $144.90 million. MediWound has a one year low of $4.25 and a one year high of $8.58.
MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. The firm had revenue of $0.69 million during the quarter, compared to the consensus estimate of $0.69 million. During the same period in the previous year, the firm earned ($0.34) EPS. The business’s revenue was up 93.8% on a year-over-year basis. Analysts forecast that MediWound will post ($0.81) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “MediWound Ltd. (MDWD) Downgraded by Zacks Investment Research” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://stocknewstimes.com/2017/08/11/mediwound-ltd-mdwd-downgraded-by-zacks-investment-research.html.
A number of hedge funds have recently added to or reduced their stakes in MDWD. Renaissance Technologies LLC raised its stake in MediWound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 1,300 shares in the last quarter. Wells Fargo & Company MN raised its stake in MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 8,745 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after buying an additional 213,745 shares in the last quarter. 27.32% of the stock is owned by institutional investors and hedge funds.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Get a free copy of the Zacks research report on MediWound (MDWD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
